Sonelokimab. Interleukin-17A and -F nanobody, Treatment of moderate to severe psoriasis, Treatment of hidradenitis suppurativa

Psoriasis is a common, chronic inflammatory disease characterized by sustained inflammation and hyperproliferation of epidermal keratinocytes. With the establishment of the interleukin (IL)-17/IL-23 pathway as a principal player in the etiopathogenesis of psoriasis, and the subsequent development of anti-IL-17/IL-23 biologics, targeted treatment for psoriasis has significantly improved within the past decade. Currently, 4 IL-17 inhibitors are approved for the treatment of moderate to severe plaque psoriasis in adults-secukinumab, ixekizumab, brodalumab and bimekizumab-all of which are monoclonal antibodies. In this scoping review article, we present the current literature on sonelokimab, a novel anti-IL-17A/F nanobody for the treatment of moderate to severe psoriasis.